Abstract
Triple-negative breast cancer (TNBC) is associated with aggressive tumor behavior, poor prognosis and BRCA1 mutations. There are limited data regarding TNBC among Algerian women. In this study, we sought to determine clinical and tumor characteristics associated with TNBC. We also screened for the prevalence of BRCA1 mutations in unselected cohort of TNBC patients. Clinical and tumor characteristics data of 877 breast cancer patients diagnosed between 2011 and 2015, were collected from cancer registry of public hospital of Rouiba. Patients were divided in two groups: those with TNBC and those with other breast cancer subtypes. Differences between the two groups with regard to clinical and tumor characteristics were compared using Fisher’s exact test. BRCA1 mutations analysis was performed in unselected cohort of 103 women with TNBC, including all exons where a mutation was previously found in Algerian population (exons 2, 3, 5, 11). The median age at diagnosis for TNBC and non-TNBC patients was 47.4 years and 49.4 years, respectively. The proportion of TNBC was 19.95%. Our data showed significant differences in menopausal status, TNM stage, histological type, tumor histological grade, Ki67 expression and family history of breast cancer between TNBC and non-TNBC patients. Four distinct deleterious mutations in BRCA1 gene were detected in eight young TNBC patients. TNBC is associated with young age, poor histopathological characteristics and family history of breast cancer. BRCA1 mutations have been detected in young TNBC patients. TNBC phenotype should be added as criterion to screen for BRCA1 mutations in Algerian women.
Similar content being viewed by others
Abbreviations
- Array–CGH:
-
Array Comparative Genomic Hybridisation
- ER:
-
Estrogen Receptor
- HER2:
-
Human Epidermal growth factor Receptor 2,
- Ki67:
-
Antigen Ki67
- IDC:
-
Invasive Ductal Carcinoma
- IHC:
-
Immunohistochemistry
- ILC:
-
Invasive Lobular Carcinoma
- IPC:
-
Infiltrating Papillary Carcinoma
- LGR:
-
Large Genomic Rearrangement
- MC:
-
Mixed Carcinoma (invasive ductal and invasive lobular)
- MLPA:
-
Multiplex Ligation Probe Amplification
- NGS:
-
Next Generation Sequencing
- PR:
-
Progesterone Receptor
References
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008 GLOBOCAN. Int J Cancer 127:2893–2917
GLOBOCAN: Breast cancer incidence and mortality worldwide (2012) International agency for research on cancer; 2012. http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp. Accessed 21 March 2016
Podo F, Buydens LMC, Degani H et al (2010) Triple_negative breast cancer: present challenges and new perspectives. Mol Oncol 4:209–229
Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7:683–692
Dent R, Trudeau M, Pritchard KI et al (2007) Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population- based study from the California cancer. Registry 109:1721–1728
Huo D, Ikpatt F, Khramtsov A et al (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple negative breast cancer. J Clin Oncol 27:4515–4521
Stark A, Kleer CG, Martin I et al (2010) African ancestry and higher prevalence of triple negative breast cancer: findings from an international study. Cancer 116:4926–4932
Amirikia KC, Mills P, Bush J, Newman LA (2011) Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer 117:2747–2753
Ly M, Antoine M, Dembélé AK et al (2012) High incidence of triple-negative tumors in sub-Saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncology 83:257–263
Su Y, Zheng Y, Zheng W et al (2011) Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population- based cohort study. BMC Cancer 11:292
Banegas MP, Tao L, Altekruse S et al (2014) Heterogeneity of breast cancer sub-types and survival among Hispanic women with invasive breast cancer in California. Breast Cancer Res Treat 144:625–634
Singh M, Ding Y, Zhang LY et al (2014) Distinct breast cancer subtypes in women with early- onset disease across races. Am J Cancer Res 4:337–352
Fourati A, Boussen H, El May MV et al (2014) Descriptive analysis of molecular subtypes in Tunisian breast cancer. Asia Pac J Clin Oncol 10:e69–e74
Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36:206–205
Wong ESY, Shekar S, Chan CHT et al Predictive factors for BRCA1 and BRCA2 genetic testing in an Asian clinic-based population. PLoS ONE 7:e0134408. doi:10.1371/journal.pone.0134408
De Ruitjter TC, Veeck J, Hoon JPJ, Van Engeland M, Tjan-Heijnen VC (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137:183–192
Robertson L, Hanson H, Seal S et al (2012) BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 106:1234–1238
Stevens KN, Vachon CM, Couch FJ (2012) Genetic susceptibility to triple-negative breast cancer. Cancer Res 7:2025–2030
Pern F, Bogdanova N, Schürmann LM et al (2012) Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital based series of German patients with triple-negative breast cancer. PLoS One 7:e47993. doi:10.1371/journal.pone.0047993
Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly (ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123–134
Tutt A, Robson M, Garber JE et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235–244
Cherbal F, Bakour R, Adane S, Boualga K (2013) BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries. Breast Dis 34:1–8
Sobin LH, Wittekind CH (2002) Breast tumors. In: Sobin LH, Wittekinds CH (eds) Classification of malignant tumors, 6th edn. Wiley-Liss, Geneva, pp 131–142
Pennacchia I, Carbone A, Di Cerbo A, Vecchio FM, Arena V (2015) 2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: impact on routine practice. Breast 24:285e6
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel members (2011) Strategies for sub- types – dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747. doi:10.1093/annonc/mdr304
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel Members (2015) Tailoring therapies-improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26:1533–1546. doi:10.1093/annonc/mdv221
Cherbal F, Bakour R, Adane S, Boualga K, Benais-Pont G, Maillet P (2010) BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. Dis Markers 28:377–384
Rais G, Raissouni S, Aitelhaj M et al (2012) Triple-negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of oncology. BMC Womens Health 12:35
Minicozzi P, Bella F, Toss A et al (2013) Relative and disease-free survival for breast cancer in relation to subtype: a population-based study. J Cancer Res Clin Oncol 139:1569–1577
Clarke CA, Keegan TH, Yang J et al (2012) Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 104:1094–1101
Rakha EA, El-Sayed ME, Green AR (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32
Ann J, Kang S, Kwun K (2008) Clinicopathologic characteristics of triple negative breast cancer in early stages. Eur J Cancer Supp 6:183
Qiu J, Xue X, Hu C et al (2016) Comparison of Clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer. J Cancer 7:167–173
Li CY, Zhang S, Zhang XB, Wang P, Hou GF, Zhang J (2013) Clinicopathological and prognostic characteristics of triple-negative breast cancer (TNBC) in Chinese patients: a retrospective study. Asian Pac J Cancer Prev 14:3779–3784
Collaborative group on Hormonal factors in Breast Cancer (2012) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360:187–195
Anothaisintawee T, Wiratkapun C, Lerdsitthichai P et al (2013) Risk factors of breast cancer: a systematic revew and meta-analysis. Asia Pac J Public Health 25:368–4943
Islami F, Liu Y, Jemal A et al (2015) Breastfeeding and breast cancer risk by receptor status- a systematic review and meta-analysis. Ann Oncol 26:2398–2407
Shinde SS, Forman MR, Kuerer HM et al (2010) Higher parity and shorter breast feeding duration: association with triple-negative phenotype of breast cancer. Cancer 116:4933–4943
Jung SY, Jeong J, Shin SH et al (2010) The invasive lobular carcinoma as a prototype luminal a breast cancer: a retrospective cohort study. BMC Cancer 10:664
Koo JS, Jung WH (2011) Clinicopathlogic and Immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J 52(1):89–97
Lee E, McKean-Cowdin R, Ma H et al (2011) Characteristics of triple negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol 29:4373–4380
Wong-Brown MW, Meldrum CJ, Carpenter JE et al (2015) Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat 50:71–80
Foulkes WD, Metcalfe K, Sun P et al (2004) Estrogen receptor status in BRCA1-BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034
Gonzalez-Angulo AM, Timms KM, Liu S et al (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17:1082–1089
Hartman AR, Kaldate RR, Sailer LM et al (2012) Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118:2787–2795
Rummel S, Varner E, Shriver CD, Ellsworth RE (2013) Evaluation of BRCA1 mutations in an unselected patient population with triple- negative breast cancer. Breast Cancer Res Treat 137:119–125
Couch FJ, Hart SN, Sharma P et al (2014) Inherited mutations in 17 breast cancer susceptibility genes among a large triple negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. doi:10.1200/JCO.2014.57.1414
Acknowledgements
We deeply thank the patients and their families for their participation. This study was supported by the Algerian National Research Program FNRSDT. FC would like to thank Dr. Philippe Maillet (Ornex, France), Prof. Kada Boualga (Anti-Cancer Center, Blida, Algeria), Daoud Cherbal and Romaissa Cherbal for their support to the research program on hereditary cancers in Algerian population.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of Interest
The authors declare non conflict of interest.
Ethical Approval
All TNBC patients tested for BRCA1 germline mutations signed written informed consent. The study was approved by the institutional review boards and ethical approval was obtained from appropriate institutions (USTHB, EPH Rouiba, FNRSDT and CNEPRU Project N° D01N01UN160420130007, 103 participants, start date: 3/07/2013, end date: 12/16/2015).
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Gaceb, H., Cherbal, F., Bakour, R. et al. Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients. Pathol. Oncol. Res. 24, 297–308 (2018). https://doi.org/10.1007/s12253-017-0242-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-017-0242-2